Basal cytokeratin expression in relation to biological factors in breast cancer

Human Pathology

Volumn 39, Issue 12, 2008, Pages 1744-1750

  Kuroda, Hajime ^a,b   Ishida, Fumitaka ^a   Nakai, Maki ^a   Ohnisi, Kiyoshi ^a   Itoyama, Shinji ^a  

^a SAITAMA MEDICAL UNIVERSITY   (Japan)

^b INTERNATIONAL UNIVERSITY OF HEALTH AND WELFARE   (Japan)

Author keywords

Breast carcinoma; Cytokeratin; Histological typing

Indexed keywords

BIOLOGICAL FACTOR; BIOLOGICAL MARKER; CYTOKERATIN; CYTOKERATIN 14; CYTOKERATIN 17; CYTOKERATIN 5; CYTOKERATIN 6; CYTOKERATIN ANTIBODY; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; GLYCOPROTEIN P; KI 67 ANTIGEN; PROGESTERONE RECEPTOR; PROTEIN P53; TRASTUZUMAB;

ADULT; AGED; ARTICLE; BASAL CELL CARCINOMA; BASAL LIKE BREAST CARCINOMA; BREAST CANCER; CHEMOSENSITIVITY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; NON BASAL LIKE BREAST CARCINOMA; PREDICTION; PROTEIN EXPRESSION;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CARCINOMA, BASAL CELL; CARCINOMA, DUCTAL, BREAST; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT; HUMANS; IMMUNOENZYME TECHNIQUES; KERATINS; KI-67 ANTIGEN; MIDDLE AGED; P-GLYCOPROTEIN; PREDICTIVE VALUE OF TESTS; RECEPTOR, ERBB-2; RECEPTORS, STEROID; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53; YOUNG ADULT;

EID: 55949125292     PISSN: 00468177     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.humpath.2008.06.007     Document Type: Article

References (38)

1. Perou C.M., Sørlie T., Eisen M.B., et al. Molecular portraits of human breast tumours. Nature 406 (2000) 747-752
2. Sørlie T., Perou C.M., Tibshirani R., et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 98 (2001) 10869-10874
3. Sorlie T., Tibshirani R., Parker J., et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A 100 (2003) 8418-8423
4. Brenton J.D., Carey L.A., Ahmed A.A., and Caldas C. Molecular classification and molecular forecasting of breast cancer: ready for clinical application?. J Clin Oncol 23 (2005) 7350-7360
5. Nielsen T.O., Hsu F.D., Jensen K., et al. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res 10 (2004) 5367-5374
6. Abd El-Rehim D.M., Ball G., Pinder S.E., et al. High-throughput protein expression analysis using tissue microarray technology of a large well-characterised series identifies biologically distinct classes of breast cancer confirming recent cDNA expression analyses. Int J Cancer 116 (2005) 340-350
7. Abd El-Rehim D.M., Pinder S.E., Paish C.E., et al. Expression of luminal and basal cytokeratins in human breast carcinoma. J Pathol 203 (2004) 661-671
8. van de Rijn M., Perou C.M., Tibshirani R., et al. Expression of cytokeratins 17 and 5 identifies a group of breast carcinomas with poor clinical outcome. Am J Pathol 161 (2002) 1991-1996
9. Fojo A.T., Ueda K., Slamon D.J., Poplack D.G., Gottesman M.M., and Pastan I. Expression of a multidrug-resistance gene in human tumors and tissues. Proc Natl Acad Sci U S A 84 (1987) 265-269
10. Biedler J.L. Genetic aspects of multidrug resistance. Cancer 70 (1992) 1799-1809
11. Caffo O., Doglioni C., Veronese S., et al. Prognostic value of p21(WAF1) and p53 expression in breast carcinoma: an immunohistochemical study in 261 patients with long-term follow-up. Clin Cancer Res 2 (1996) 1591-1599
12. Dublin E.A., Miles D.W., Rubens R.D., Smith P., and Barnes D.M. p53 immunohistochemical staining and survival after adjuvant chemotherapy for breast cancer. Int J Cancer 74 (1997) 605-608
13. Bebenek M., Bar J.K., Harlozinska A., and Sedlaczek P. Prospective studies of p53 and c-erbB-2 expression in relation to clinicopathological parameters of human ductal breast cancer in the second stage of clinical advancement. Anticancer Res 18 (1998) 619-623
14. Reed W., Hannisdal E., Boehler P.J., Gundersen S., Host H., and Marthin J. The prognostic value of p53 and c-erb B-2 immunostaining is overrated for patients with lymph node negative breast carcinoma: a multivariate analysis of prognostic factors in 613 patients with a follow-up of 14-30 years. Cancer 88 (2000) 804-813
15. Wintzer H.O., Zipfel I., Schulte-Mönting J., Hellerich U., and von Kleist S. Ki-67 immunostaining in human breast tumors and its relationship to prognosis. Cancer 67 (1991) 421-428
16. Pinder S.E., Wencyk P., Sibbering D.M., et al. Assessment of the new proliferation marker MIB1 in breast carcinoma using image analysis: associations with other prognostic factors and survival. Br J Cancer 71 (1995) 146-149
17. Brown R.W., Allred C.D., Clark G.M., Osborne C.K., and Hilsenbeck S.G. Prognostic value of Ki-67 compared to S-phase fraction in axillary node-negative breast cancer. Clin Cancer Res 2 (1996) 585-592
18. Burcombe R.J., Makris A., Richman P.I., et al. Evaluation of ER, PgR, HER-2 and Ki-67 as predictors of response to neoadjuvant anthracycline chemotherapy for operable breast cancer. Br J Cancer 92 (2005) 147-155
19. Malzahn K., Mitze M., Thoenes M., and Moll R. Biological and prognostic significance of stratified epithelial cytokeratins in infiltrating ductal breast carcinomas. Virchows Arch 433 (1998) 119-129
20. Kim M.J., Ro J.Y., Ahn S.H., Kim H.H., Kim S.B., and Gong G. Clinicopathologic significance of the basal-like subtype of breast cancer: a comparison with hormone receptor and Her2/neu-overexpressing phenotypes. Hum Pathol 37 (2006) 1217-1226
21. Foulkes W.D., Brunet J.S., Stefansson I.M., et al. The prognostic implication of the basal-like (cyclin E high/p27 low/p53+/glomeruloid-microvascular-proliferation+) phenotype of BRCA1-related breast cancer. Cancer Res 64 (2004) 830-835
22. Korsching E., Packeisen J., Agelopoulos K., et al. Cytogenetic alterations and cytokeratin expression patterns in breast cancer: integrating a new model of breast differentiation into cytogenetic pathways of breast carcinogenesis. Lab Invest 82 (2002) 1525-1533
23. el-Deiry W.S. Regulation of p53 downstream genes. Semin Cancer Biol 8 (1998) 345-357
24. Yamashiro H., and Toi M. Update of evidence in chemotherapy for breast cancer. Int J Clin Oncol 13 (2008) 3-7
25. Carey L.A., Dees E.C., Sawyer L., et al. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res 13 (2007) 2329-2334
26. Makris A., Powles T.J., Allred D.C., et al. Quantitative changes in cytological molecular markers during primary medical treatment of breast cancer: a pilot study. Breast Cancer Res Treat 53 (1999) 51-59
27. Assersohn L., Salter J., Powles T.J., et al. Studies of the potential utility of Ki67 as a predictive molecular marker of clinical response in primary breast cancer. Breast Cancer Res Treat 82 (2003) 113-123
28. Burcombe R., Wilson G.D., Dowsett M., et al. Evaluation of Ki-67 proliferation and apoptotic index before, during and after neoadjuvant chemotherapy for primary breast cancer. Breast Cancer Res 8 (2006) R31
29. Rouzier R., Perou C.M., Symmans W.F., et al. Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res 11 (2005) 5678-5685
30. Trambas C.M., Muller H.K., and Woods G.M. P-glycoprotein mediated multidrug resistance and its implications for pathology. Pathology 29 (1997) 122-130
31. Ota E., Abe Y., Oshika Y., et al. Expression of the multidrug resistance-associated protein (MRP) gene in non-small-cell lung cancer. Br J Cancer 72 (1995) 550-554
32. Chuman Y., Sumizawa T., Takebayashi Y., et al. Expression of the multidrug-resistance-associated protein (MRP) gene in human colorectal, gastric and non-small-cell lung carcinomas. Int J Cancer 66 (1996) 274-279
33. Endo K., Maehara Y., Kusumoto T., Ichiyoshi Y., Kuwano M., and Sugimachi K. Expression of multidrug-resistance-associated protein (MRP) and chemosensitivity in human gastric cancer. Int J Cancer 68 (1996) 372-377
34. Alexander D., Yamamoto T., Kato S., and Kasai S. Histopathological assessment of multidrug resistance in gastric cancer: expression of P-glycoprotein, multidrug resistance-associated protein, and lung-resistance protein. Surg Today 29 (1999) 401-406
35. Wright S.R., Boag A.H., Valdimarsson G., et al. Immunohistochemical detection of multidrug resistance protein in human lung cancer and normal lung. Clin Cancer Res 4 (1998) 2279-2289
36. Mechetner E., Kyshtoobayeva A., Zonis S., et al. Levels of multidrug resistance (MDR1) P-glycoprotein expression by human breast cancer correlate with in vitro resistance to taxol and doxorubicin. Clin Cancer Res 4 (1998) 389-398
37. Schneider J., Gonzalez-Roces S., Pollán M., et al. Expression of LRP and MDR1 in locally advanced breast cancer predicts axillary node invasion at the time of rescue mastectomy after induction chemotherapy. Breast Cancer Res 3 (2001) 183-191
38. Burger H., Foekens J.A., Look M.P., et al. RNA expression of breast cancer resistance protein, lung resistance-related protein, multidrug resistance-associated proteins 1 and 2, and multidrug resistance gene 1 in breast cancer: correlation with chemotherapeutic response. Clin Cancer Res 9 (2003) 827-836